Recent Updates
Recently added Catalysts
DTIL Positive Sentiment

Precision BioSciences to Report First Quarter 2025 Results on May 15, 2025

Thursday, May 8, 2025 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Precision BioSciences, a clinical stage gene editing company, announced it will report its first quarter 2025 results on May 15, 2025. The company utilizes its proprietary ARCUS platform to develop in vivo gene editing therapies aimed at addressing diseases with significant unmet medical needs. This report is anticipated to shed light on their advancements and future directions.
Price reaction · baseline $5.18 (2025-05-07 close) · hit pre-market · clean, no other DTIL news in the window
day 0 close
-0.6%

Market Sentiment Analysis

POSITIVE FACTORS

  • Precision BioSciences is advancing its gene editing therapies.
  • The company is addressing diseases with high unmet need.
  • The upcoming report may provide insights into their progress.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+24%
120-day peak, hindsight
Typical move
4.8%
average across 2 past catalysts
Cash runway
~19 mo
Low dilution risk
Lead asset
Targeted CEA CAR-T
Phase 1 · Advanced Lung Cancer

Full Press Release Details

DURHAM, N.C. –(BUSINESS WIRE)–May 8, 2025– Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS ® platform to develop in vivo gene editing therapies for diseases with high unmet need, today announced that it will publish

Frequently Asked Questions

When will Precision BioSciences report Q1 2025 results?

Precision BioSciences will report its Q1 2025 results on May 15, 2025.

What platform does Precision BioSciences use?

The company utilizes its proprietary ARCUS platform for gene editing.

What is the focus of Precision BioSciences' therapies?

Their therapies aim to address diseases with high unmet medical needs.

ShareAdd on Google
Tags: DTIL Viatris Investor Conferences Healthcare Precision BioSciences gene editing ARCUS platform clinical stage
Last updated: May 8, 2025

Biotech snapshot

Cash runway
$88M liquidity · $4M/mo burn
~19 mo
Low dilution risk
Lead asset
Targeted CEA CAR-TPhase 1
Advanced Lung Cancer →

Catalyst track record

+24%
best trade around DTIL's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for DTIL.

See every catalyst's timing & PoA →